Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

By L. Zitvogel, L. Galluzzi, M. Smyth, Guido Kroemer. Immunity, 2013

815 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/ed6eea832e8aa60edc7677d1363c504b01121f8a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Zitvogel
3. L. Galluzzi
4. M. Smyth
5. Oliver Kepp
6. S. Formenti
7. S. Demaria
8. A. Buqué

In Oncology

1. Guido Kroemer
2. L. Galluzzi
3. L. Zitvogel
4. S. Formenti
5. S. Demaria
6. Oliver Kepp
7. M. Smyth
8. Daniel S. Chen

Citations in the corpus

• Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium (2018, background): “The tumor microenvironment is able to induce the overexpression of CTLA-4 that binds the stimulating protein CD80 and CD86 present in the antigen presenting cells preventing their interaction with the T-cell surface receptor, responsible for the activation of immune system against cancer cells (Zitv”
• The Two Faces of IL-6 in the Tumor Microenvironment (2014, background): “The status of host adaptive immunity has surprisingly broad implications since CD8+ effector T cells have been shown to be necessary not only for anti-tumor immunity, but also for the efficacy of standard anti-cancer regimens including chemotherapy and radiation [66,67].”
• Consensus guidelines for the detection of immunogenic cell death (2014, background): “Indeed, even the activity of antineoplastic regimens that fail to render dying cells immunogenic but induce other immunostimulatory effects is negatively affected by the absence of a functional immune system.(104,105) Among other molecules, this applies to the microtubular inhibitor paclitaxel and t”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…contrary, specific immunosuppressive circuits were inactivated demonstrate that many chemotherapeutic agents that were initially developed according to a purely cancer cell-autonomous logics mediate antineoplastic effects via immunological mechanisms (Galluzzi et al., 2012; Zitvogel et al., 2013).”